Loading

Panel – Re-evaluating our strategies for combination partnering

11 Sep 2018

14:50 - 15:30

Immuno-Oncology Frontiers Europe

How does BMS’s selection of a single preferential partner impact biotech and big pharma?
What are the most effective partnering models in their eyes for combination development?
If you are a biotech – should you seek to partner right up front? Or try to go it alone?

Chairperson

Victoria English, Editor - MedNous

Speakers

Bernd Muehlenweg, CBO - Nanobiotix

Mark Throsby, CSO - Merus N.V.

Ro Wickramsinghe , Directory of Oncology Evaluation - AstraZeneca

Testimonials

Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities

Jean-Philippe Combal
GenSight Biologics
The conference consistently proves to be a great forum for networking with industry leaders in the development of cellular and gene therapies as well as vendors for important technologies and services.

Michael Covington
Juno Therapeutics, Inc
It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance

Bertrand Alexandre
Celyad
Phacilitate EU delivered it's promise and more, the topics discussed were highly relevant, with very good and professional speakers and panelists. You will see me next year in Berlin.

Dr Ohad Karnieli
Karnieli Ltd